Truemeds Boosts Margins and Decodes Pricing in the Generics Game
Breaking the Code: How Truemeds is Revolutionizing India’s Generic Medicine Market
India’s pharmaceutical sector, valued at a whopping $66.66 billion, is in the middle of a chronic healthcare crisis. The rising medical expenses are putting a massive strain on Indian households, with the average rural Indian shelling out INR 135 per month, while city dwellers are paying INR 250, according to the government’s monthly consumption expenditure survey. Yet, despite being home to the 14th largest pharma industry globally and a leading supplier of generic drugs, India is battling a severe healthcare gap, with over 1.6 million lives lost annually due to inadequate healthcare services.
This paradox is exacerbated by India’s poor healthcare infrastructure, high pollution levels, and limited access to quality medical professionals. As a result, drug dependency is on the rise, while the cost of branded medicines continues to add pressure on household budgets.
Enter Truemeds, a game-changer in India’s pharmaceutical landscape.
Bridging the Affordability Gap Founded by Akshat Nayyar and Dr. Kunal Wani, Truemeds emerged with a mission to deliver affordable healthcare by focusing on generic medicines. With the rising costs of branded drugs in a market known for its affordable generics, Truemeds sought to break the brand-driven ecosystem that had been dominating India’s healthcare for decades.
Nayyar, a former employee of global pharma major Abbott, noticed an opportunity when the Medical Council of India (MCI) mandated that doctors should prescribe drugs by their salt (generic) names rather than brand names. While the mandate faced resistance from some doctors, the government doubled down in 2018, requiring that generic names be printed in a larger font than brand names on prescriptions. This move was aimed at reducing the strong influence of pharmaceutical companies on doctors and making medications more accessible and affordable for patients.
Disrupting the Pharma Ecosystem Truemeds began as a listing platform for generic alternatives, allowing patients to compare different medicines much like Zomato’s early model for restaurant discovery. However, the growing demand from consumers led Truemeds to evolve into a full-fledged medicine delivery service. The company capitalized on the need for affordable medicines and linked accessibility directly with affordability, offering a unique value proposition in India’s pharmaceutical market.
Despite competition from other players in the market, such as Tata 1mg and PharmEasy, Truemeds has raised over $100 million in funding, including a recent $85 million round led by Accel and Peak XV Partners. But what sets Truemeds apart from its competitors is its focus on offering the right value for money, ensuring both quality and affordability for patients.
The Profitability of Generic Medicines The real challenge in executing a successful generic drug model at scale lies in distribution. While branded medicines benefit from a well-established and predictable supply chain, generics face a fragmented distribution system, often resulting in patchy and inconsistent availability.
Truemeds recognized this gap and partnered with smaller generic drug manufacturers to generate demand for their products. This enabled Truemeds to capture higher margins and pass on the savings to consumers, all while offering quality generic alternatives. Unlike the branded pharmaceutical system, where companies retain 60-70% of the margin due to advertising and marketing, Truemeds flips the structure. It captures 50-60% margins before discounts and 20-30% after discounts, all while offering medicines at a much lower price point.
This model has been a success, with Truemeds achieving a topline of INR 510 crore in FY25, marking a 57% increase year-on-year. The company has also expanded its offerings to include vitamins, oral care products, and other essentials, further tapping into the growing healthcare wallet of Indian consumers.
The Future of Truemeds For Truemeds, customer education and acquisition remain the biggest hurdles. Unlike traditional pharmacies, which rely on prescriptions for demand, Truemeds has to convince consumers to shift from branded drugs to generic substitutes. This has required substantial marketing efforts and awareness campaigns to educate the public about the benefits of generic drugs.
While generic medicine platforms have struggled to scale, Truemeds has found success by focusing on customer retention. Once a consumer starts saving 40-50% on chronic illness medicines, they are likely to stay loyal to the platform.
In the coming years, Truemeds plans to expand its services further, especially in diagnostics. The startup is planning to launch blood tests in select Tier II and Tier III towns, where healthcare services are often limited.
Sustainability in Healthcare Truemeds’ journey is a testament to the power of innovation and entrepreneurship in solving India’s healthcare crisis. By focusing on generic medicines, Truemeds is offering a sustainable solution to the ever-growing pharmaceutical market, bridging the gap between affordability and accessibility.
However, for Truemeds to make true progress, India must overcome its reluctance to embrace generics. Despite their significant cost advantages, branded drugs still dominate the market, making it difficult for consumers to switch to generic alternatives.
The road ahead is challenging, but with its strong operational model and commitment to improving healthcare access, Truemeds is well-positioned to lead the charge in India’s healthcare transformation.
